Evaluation of dual BCL-2/BCL-XL inhibition in acute myeloid leukemia preclinical models with and without prior venetoclax therapy. Shah R, Kingston N, Fabbri G, Saeh J, et al. Exp Hematol 2026;156:105379.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shah R, Kingston N, Fabbri G, Saeh J, et al. Evaluation of dual BCL-2/BCL-XL inhibition in acute myeloid leukemia preclinical models with and without prior venetoclax therapy. Exp Hematol 2026;156:105379.
PMID: 41534681